Q32 Bio (QTTB) Cash & Equivalents (2017 - 2026)

Q32 Bio has reported Cash & Equivalents for 10 years, with the latest figure at $50.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 22.5% year-over-year to $50.8 million; the trailing twelve-month figure through Mar 2026 stood at $50.8 million (down 22.5% YoY), and the FY2025 full-year result was $48.3 million, down 38.05% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $50.8 million, up from $48.3 million in the prior quarter.
• The five-year high for Cash & Equivalents was $248.1 million in Q1 2022, with the low at $20.1 million in Q2 2023.
• Average Cash & Equivalents over 5 years is $74.3 million, with a median of $50.8 million recorded in 2026.
• Year-over-year, Cash & Equivalents tumbled 88.62% in 2023 and jumped 386.94% in 2024.
• Tracing QTTB's Cash & Equivalents over 5 years: stood at $34.0 million in 2022, then dropped by 24.62% to $25.6 million in 2023, then soared by 204.35% to $78.0 million in 2024, then sank by 38.05% to $48.3 million in 2025, then rose by 5.08% to $50.8 million in 2026.
• The last three Cash & Equivalents figures came in at $50.8 million (Q1 2026), $48.3 million (Q4 2025), and $49.0 million (Q3 2025), per Business Quant data.

Peer Comparison